Buprenorphine Blocks ϵ- and μ-Opioid Receptor-Mediated Antinociception in the Mouse

  title={Buprenorphine Blocks ϵ- and $\mu$-Opioid Receptor-Mediated Antinociception in the Mouse},
  author={Hirokazu Mizoguchi and Amanda Spaulding and Randy J. Leitermann and Hsiang-En Wu and Hiroshi Nagase and Leon F. Tseng},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={394 - 400}
Antagonistic properties of buprenorphine for ϵ- and μ-opioid receptors were characterized in β-endorphin- and [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO)-induced antinociception, respectively, with the tail-flick test in male ICR mice. ϵ-Opioid receptor agonist β-endorphin (0.1–1 μg), μ-opioid receptor agonist DAMGO (0.5–20 ng), or buprenorphine (0.1–20 μg) administered i.c.v. dose dependently produced antinociception. The antinociception induced by 10 μg of buprenorphine given i.c.v. was… 

Figures and Tables from this paper

Buprenorphine: a unique drug with complex pharmacology.
Evidence is provided demonstrating that the ORL-1 receptor plays a functional role not only in the antinociceptive effect of buprenorphine but also in other actions of the drug as well.
The history and pharmacology of buprenorphine: New advances in cats.
  • T. Clark
  • Biology, Medicine
    Journal of veterinary pharmacology and therapeutics
  • 2022
The history and pharmacology of buprenorphine relative to full opioid agonists, where appropriate, are examined, integrating these insights into advances within feline medicine.
Antinociceptive effects of intravenous administration of hydromorphone hydrochloride alone or followed by buprenorphine hydrochloride or butorphanol tartrate to healthy conscious cats.
Butorphanol administration decreased the duration of antinociception achieved with hydromorphone administration in cats, and this opioid interaction and its impact on pain management require additional investigation.
Mechanism-Based Pharmacokinetic-Pharmacodynamic Modelling of the Reversal of Buprenorphine-Induced Respiratory Depression by Naloxone
Because of the slow receptor association-dissociation Kinetics of buprenorphine in combination with the fast elimination kinetics of naloxone, nal oxone is best administered as a continuous infusion for reversal of buPrenorphines-induced respiratory depression.
Advances in the delivery of buprenorphine for opioid dependence
Clinical trial data for novel buprenorphine delivery systems in the form of subcutaneous depot injections, transdermal patches, and subdermal implants for the treatment of OUD are reviewed and both the clinical efficacy of longer-acting formulations through increasing consistent medication exposure and their potential utility in reducing diversion are discussed.


Antinociceptive effect of buprenorphine in mu1-opioid receptor deficient CXBK mice.
Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors.
The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat.
It is reported for the first time that intrathecal buprenorphine is approximately 17 times more effective than hydromorphone in inhibiting thermal pain, and bupenorphine produces its antinociceptive effect by acting as an agonist at both mu- and kappa-spinal opioid receptors.
The Role of Spinal Opioid Receptors in Antinociceptive Effects Produced by Intrathecal Administration of Hydromorphone and Buprenorphine in the Rat
Intrathecally-administered hydromorphone and buprenorphine produced a dose- and time-dependent increase in the tail-flick response latency in rats, and naloxone administered intrathecally was effective in preventing the antinociceptive effects of subsequent intrathecal injections of bupenorphine.
Different types of opioid receptors mediating analgesia induced by morphine, DAMGO, DPDPE, DADLE and β-endorphin in mice
Results indicate that analgesia induced by morphine and DAMGO is mediated by the stimulation of mu-opioid receptors while analgesiainduced by DPDPE ismediated by the stimulating of delta-opIOid receptors.
Involvement of epsilon and kappa opioid receptors in inhibition of the tail-flick response induced by bremazocine in the mouse.
The present studies were designed to determine what types of opioid receptors and neurotransmitters were involved in inhibiting the tail-flick response induced by bremazocine in male ICR mice.